Aytu BioPharma, Inc.
Aytu BioPharma, Inc. (Nasdaq: AYTU) is a pharmaceutical company focused on commercializing prescription medicines, primarily for central nervous system conditions. Its portfolio includes EXXUA, an extended-release treatment for major depressive disorder in adults; Adzenys and Cotempla, extended-release orally… From the company’s description.
In fiscal 2026, Aytu BioPharma, Inc. reported revenue of $57.57M, down 13.3% from fiscal 2025, and a net loss of $14.25M. Its operating margin was −14.4%, and operations generated $3.28M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure.
What Aytu BioPharma, Inc. does
In the company’s own words
Aytu BioPharma, Inc. (Nasdaq: AYTU) is a pharmaceutical company focused on commercializing prescription medicines, primarily for central nervous system conditions. Its portfolio includes EXXUA, an extended-release treatment for major depressive disorder in adults; Adzenys and Cotempla, extended-release orally disintegrating stimulant medications for ADHD; and Karbinal ER, an extended-release antihistamine suspension for allergic conditions, particularly in children. The company sells mainly in the United States through wholesalers, distributors and pharmacies, and supports patient access through its Aytu RxConnect network of more than 1,000 pharmacies. Aytu operates as one business and reporting segment; in fiscal 2026, net revenue was $57.6 million, including $45.8 million from its ADHD portfolio, $6.6 million from EXXUA and $5.1 million from its Pediatric Portfolio. It launched EXXUA during fiscal 2026 under an exclusive U.S. commercialization agreement and divested its Consumer Health business in 2024, concentrating operations on prescription products. Its brands include EXXUA, Adzenys, Cotempla and Karbinal.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- DENVER, CO
- Fiscal year end
- June
- CIK
- 1385818
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2026 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Aytu BioPharma, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Aytu BioPharma, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Aytu BioPharma, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Aytu BioPharma, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Aytu BioPharma, Inc.'s last four quarterly filings that the numbers alone won't show?”